“Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s100. doi:10.25251/skin.4.supp.100.